Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: A retrospective observational cohort study in a US claims database

BMC Health Services Research

Volumn 15, Issue 1, 2015, Pages

  Kyaw, Moe H ^a,b   Kern, David M ^c   Zhou, Siting ^c   Tunceli, Ozgur ^c   Jafri, Hasan S ^a   Falloon, Judith ^a  

^a MEDIMMUNE   (United States)

^b SANOFI PASTEUR   (France)

^c HEALTHCORE INC   (United States)

Author keywords

Health economics; ICU; P. aeruginosa; Pneumonia; Resource utilization; S. aureus

Indexed keywords

ADULT; AGED; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CROSS INFECTION; ECONOMICS; FACTUAL DATABASE; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; UNITED STATES; UTILIZATION;

ADULT; AGED; COHORT STUDIES; CRITICAL CARE; CROSS INFECTION; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 84931094629     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-015-0917-x     Document Type: Article

References (30)

1. Gaynes R, Edwards JR. National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848-54.
2. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: Results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854-62.
3. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest. 2002;122:2183-96.
4. Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo LM, et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med. 2010;182:1533-9.
5. Park DR. The microbiology of ventilator-assisted pneumonia. Resp Care. 2005;50:742-65.
6. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10:R97.
7. Bou R, Lorente L, Aguilar A, Perpiñán J, Ramos P, Peris M, et al. Hospital economic impact of an outbreak of Pseudomonas aeruginosa infections. J Hosp Infect. 2009;71:138-42.
8. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med. 2005;165:1756-61.
9. Rello J, Diaz E. Pneumonia in the intensive care unit. Crit Care Med. 2003;31:2544-51.
10. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. 1999;5:9-17.
11. Schreiber MP, Chan CM, Shorr AF. Bacteremia in Staphylococcus aureus pneumonia: outcomes and epidemiology. J Crit Care. 2011;26:395-401.
12. Shorr A, Lodise TP. Burden of Methicillin-resistant Staphylococcus aureus on healthcare cost and resource utilization. ISMR Update. 2006;1:1-12.
13. Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med. 2006;34:700-6.
14. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Centers for Disease Control and Prevention; 2013. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
15. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999;159:1127-32.
16. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010;31:47-53.
17. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54:109-15.
18. Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122.
19. DiGiandomenico A, Camara M, Keller A, Thaden JT, Guenther C, Shire N, Fowler VG, Stover CK. MEDI3902 PcrV and Psl Target Validation in Pseudomonas aeruginosa Clinical Isolates and Analysis of Target Activity in Matched Patient Serum Samples. In: Interscience Conference on Antimicrobial Agents and Chemotherapy 2014 Online Abstracts. American Society for Microbiology. 2014. http://www.icaaconline.com/php/icaac2014abstracts/data/index.htm.
20. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014;43:29874-80.
21. Nadathur SG. Comorbidity indexes from administrative datasets: what is measured? Aust Health Rev. 2011;35:507-11.
22. Eber MR, Laxminarayan R, Perencevich EN, Malani A. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med. 2010;170:347-53.
23. Dietrich ES, Demmler M, Schulgen G, Fekec K, Mast O, Pelz K, et al. Nosocomial pneumonia: a cost-of-illness analysis. Infection. 2002;30:61-7.
24. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol. 2012;33:250-6.
25. Restrepo MI, Anzueto A, Arroliga AC, Afessa B, Atkinson MJ, Ho NJ, et al. Economic burden of ventilator-associated pneumonia based on total resource utilization. Infect Control Hosp Epidemiol. 2010;31:509-15.
26. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418-28.
27. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, et al. VAP Outcomes Scientific Advisory Group. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122:2115-21.
28. O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res. 2005;40:1620-39.
29. Halpern NA, Pastores SM. Critical care medicine in the United States 2000-2005: An analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med. 2010;38:65-71.
30. Mullins PM, Goyal M, Pines JM. National growth in intensive care unit admissions from emergency departments in the United States from 2002 to 2009. Acad Emerg Med. 2013;20:479-86.